Magazine article Clinical Psychiatry News

Aripiprazole Approved for Autism-Related Irritability

Magazine article Clinical Psychiatry News

Aripiprazole Approved for Autism-Related Irritability

Article excerpt

The Food and Drug Administration's approval of the atypical antipsychotic aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents aged 6-17 years provides physicians with one more option for this indication--which includes symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

Risperidone (Risperdal), also an atypical antipsychotic, was approved in 2006 for the same indication for children aged 5-16 years.

Aripiprazole, marketed as Abilify by the manufacturers, Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co., was initially approved by the FDA in 2002 for schizophrenia. Aripiprazole has been approved for several other adult and pediatric indications, including treatment of schizophrenia in adolescents aged 13-17 years, and bipolar disorder indications down to age 10 years. The recommended dose for the new indication is 5-10 mg day (starting at 2 mg per day, with the maximum dose of 15 mg per day).

The effectiveness of aripiprazole for the autistic disorder indication was established in two 8-week multicenter studies of children and adolescents aged 6-17 years (more than 75% were younger than age 13 years), according to the revised label. They met the DSM-IV criteria for autistic disorder and exhibited behaviors that included tantrums, aggression, and/or self-injurious behavior.

In one study of 98 children and adolescents, those on aripiprazole (at a starting dose of 2 mg/day increasing up to 15 mg per day based on clinical response), had significantly improved scores when compared to those on placebo at 8 weeks on two scales: the irritability subscale of the Aberrant Behavior Checklist (ABC-I), a caregiver-rated assessment tool, and the Clinical Global Impression-Improvement (CGI-I) scale, a tool used to monitor treatment outcomes in psychiatric disorders. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.